Benzinga

Benzinga

Benzinga

mardi, septembre 01

Quest Diagnostics Inc

DGXNYSE
Trade with Public
Trade with Public
$240.30
-2.46-1.01%
À la clôture: Aug 31, 5:00 PM EST
$240.30
N/A
Après les heures: 4:02 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Quest Diagnostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quest Diagnostics (DGX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

7Buy
8Hold
Consensus RatingNeutral# Analysts15Avg. Consensus PT$212Upside to Avg. PT-12.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026JP MorganLisa GillPT RaiseNeutral$220→$250
Jul 24, 2026UBSKevin CaliendoPT RaiseNeutral$220→$232
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved